Longitudinal serum neurofilament light chain (sNfL) concentration relates to cognitive function in multiple sclerosis patients.

Bookmark(0)

No account yet? Register

Serum neurofilament light chain (sNfL) may be used as a biological marker of disease progression in multiple sclerosis (MS), although longitudinal studies correlating cognitive deficits to sNfL are limited.To longitudinally […]

» Read more

Oral therapies for treatment of relapsing-remitting multiple sclerosis in Austria: a 2-year comparison using an inverse probability weighting method.

Bookmark(0)

No account yet? Register

To compare the efficacies, frequencies and reasons for treatment interruption of fingolimod (FTY), dimethyl fumarate (DMF) or teriflunomide (TERI) in a nationwide observational cohort.Two cohorts of patients with relapsing-remitting multiple […]

» Read more

Impaired connectivity within neuromodulatory networks in multiple sclerosis and clinical implications.

Bookmark(0)

No account yet? Register

There is mounting evidence regarding the role of impairment in neuromodulatory networks for neurodegenerative diseases, such as Parkinson’s and Alzheimer’s disease. However, the role of neuromodulatory networks in multiple sclerosis […]

» Read more

Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study.

Bookmark(0)

No account yet? Register

High-efficacy therapies in multiple sclerosis are traditionally used after unsuccessful treatment with first-line disease modifying therapies. We hypothesised that early commencement of high-efficacy therapy would be associated with reduced long-term […]

» Read more

Effect of fingolimod on MRI outcomes in patients with paediatric-onset multiple sclerosis: results from the phase 3 PARADIGMS study.

Bookmark(0)

No account yet? Register

PARADIGMS demonstrated superior efficacy and comparable safety of fingolimod versus interferon β-1a (IFN β-1a) in paediatric-onset multiple sclerosis (PoMS). This study aimed to report all predefined MRI outcomes from this […]

» Read more

Efficacy of inpatient personalized multidisciplinary rehabilitation in multiple sclerosis: behavioural and functional imaging results.

Bookmark(0)

No account yet? Register

Although multidisciplinary rehabilitation programs are commonly used in clinical practice for patients with multiple sclerosis (MS), they are currently underexamined.This study aims to investigate the efficacy and underlying brain mechanisms […]

» Read more

Pregnancy outcomes in interferon-beta-exposed patients with multiple sclerosis: results from the European Interferon-beta Pregnancy Registry.

Bookmark(0)

No account yet? Register

Family planning is an important consideration for women with multiple sclerosis (MS), who are often diagnosed during their reproductive years. Currently, limited data are available on pregnancy outcomes in patients […]

» Read more

Advances in oral immunomodulating therapies in relapsing multiple sclerosis.

Bookmark(0)

No account yet? Register

Oral treatment options for disease-modifying therapy in relapsing multiple sclerosis have substantially increased over the past decade with four approved oral compounds now available: fingolimod, dimethyl fumarate, teriflunomide, and cladribine. […]

» Read more

Volume loss in the deep gray matter and thalamic subnuclei: a longitudinal study on disability progression in multiple sclerosis.

Bookmark(0)

No account yet? Register

Volume loss in the deep gray matter (DGM) has been reported in patients with multiple sclerosis (MS) already at early stages of the disease and is thought to progress throughout […]

» Read more

Distinct influence of different vascular risk factors on white matter brain lesions in multiple sclerosis.

Bookmark(0)

No account yet? Register

To determine if vascular risk factor (VRF), that is, smoking, arterial hypertension (HT), dyslipidaemia and diabetes, have an effect on multiple sclerosis (MS) pathology as measured by MS typical brain […]

» Read more

Effects of disease-modifying therapy on peripheral leukocytes in patients with multiple sclerosis.

Bookmark(0)

No account yet? Register

Modern disease-modifying therapies (DMTs) in multiple sclerosis (MS) have variable modes of action and selectively suppress or modulate the immune system. In this review, we summarize the predicted and intended […]

» Read more

A longitudinal study of cognitive function in multiple sclerosis: is decline inevitable?

Bookmark(0)

No account yet? Register

Numerous cross-sectional studies report cognitive impairment in multiple sclerosis (MS), but longitudinal studies with sufficiently long-term follow-up are scarce.We aimed to investigate the cognitive 10-year course of a cohort of […]

» Read more

Efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis (MS-SMART): a phase 2b, multiarm, double-blind, randomised placebo-controlled trial.

Bookmark(0)

No account yet? Register

Neurodegeneration is the pathological substrate that causes major disability in secondary progressive multiple sclerosis. A synthesis of preclinical and clinical research identified three neuroprotective drugs acting on different axonal pathobiologies. […]

» Read more

Minimal evidence of disease activity (MEDA) in relapsing-remitting multiple sclerosis.

Bookmark(0)

No account yet? Register

This study aimed to define the minimal evidence of disease activity (MEDA) during treatment that can be tolerated without exposing patients with relapsing-remitting multiple sclerosis at risk of long-term disability.We […]

» Read more

Quantity and quality of gait and turning in people with multiple sclerosis, Parkinson’s disease and matched controls during daily living.

Bookmark(0)

No account yet? Register

Clinical trials need to specify which specific gait characteristics to monitor as mobility measures for each neurological disorder. As a first step, this study aimed to investigate a set of […]

» Read more

A multimodal approach to assess the validity of atrophied T2-lesion volume as an MRI marker of disease progression in multiple sclerosis.

Bookmark(0)

No account yet? Register

Atrophied T2-lesion volume (LV) is a novel MRI marker representing brain-lesion loss due to atrophy, able to predict long-term disability progression and conversion to secondary-progressive multiple sclerosis (MS).To better characterize […]

» Read more

Clinically stable disease is associated with a lower risk of both income loss and disability pension for patients with multiple sclerosis.

Bookmark(0)

No account yet? Register

To assess the risk of losing income from salaries and risk disability pension for multiple sclerosis patients with a clinically stable disease course 3 years after the start of disease-modifying therapy […]

» Read more

Exit strategies for “needle fatigue” in multiple sclerosis: a propensity score-matched comparison study.

Bookmark(0)

No account yet? Register

Patients with multiple sclerosis on long-term injectable therapies may suffer from the so-called “needle fatigue”, i.e., a waning commitment to continue with the prescribed injectable treatment. Therefore, alternative treatment strategies […]

» Read more

Racial differences in systemic sclerosis disease presentation: a European Scleroderma Trials and Research group study.

Bookmark(0)

No account yet? Register

Racial factors play a significant role in SSc. We evaluated differences in SSc presentations between white patients (WP), Asian patients (AP) and black patients (BP) and analysed the effects of […]

» Read more

sDietary and pharmacological fatty acids and cardiovascular health.

Bookmark(0)

No account yet? Register

The effects of dietary intake of different fatty acids and pharmacological use of fatty acids, specifically long-chain n-3 polyunsaturated fatty acids (LC n-3 PUFAs), on cardiovascular health and atherosclerotic cardiovascular […]

» Read more

Cannabinoids for the treatment of mental disorders and symptoms of mental disorders: a systematic review and meta-analysis.

Bookmark(0)

No account yet? Register

Medicinal cannabinoids, including medicinal cannabis and pharmaceutical cannabinoids and their synthetic derivatives, such as tetrahydrocannabinol (THC) and cannabidiol (CBD), have been suggested to have a therapeutic role in certain mental […]

» Read more
1 2 3